Related Experiment Video
Updated: Jun 22, 2026
10:13
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Genetics: Predictive value of KRAS mutations in chemoresistant CRC
Astrid Lièvre1, Pierre Laurent-Puig
1INSERM Laboratory, Paris, France.
Nature Reviews. Clinical Oncology
|June 2, 2009
Summary
KRAS mutations predict resistance to cetuximab, an anti-EGFR antibody, in patients with chemoresistant colorectal cancer. These mutations indicate a lack of survival benefit from this targeted therapy.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Colorectal cancer (CRC) is a significant global health concern.
- Epidermal Growth Factor Receptor (EGFR) targeted therapies, like cetuximab, are used in CRC treatment.
- Predictive biomarkers are crucial for optimizing treatment strategies in CRC.
Purpose of the Study:
- To evaluate KRAS mutation status as a predictive marker for cetuximab efficacy in patients with chemoresistant colorectal cancer.
- To determine if KRAS mutations are associated with resistance to anti-EGFR therapy.
- To assess the impact of KRAS mutations on survival outcomes in this patient population.
Main Methods:
- Analysis of KRAS gene mutations.
- Utilizing data from the CO.17 randomized, controlled, phase III study.
- Correlating KRAS mutation status with patient response and survival to cetuximab treatment.
Main Results:
- KRAS mutations were identified as a significant factor in predicting treatment outcomes.
- Patients with KRAS mutations showed resistance to cetuximab therapy.
- No survival benefit was observed in patients with KRAS mutations treated with cetuximab.
Conclusions:
- KRAS mutations serve as a valid predictive marker for resistance to cetuximab in chemoresistant colorectal cancer.
- Targeted therapy with cetuximab is unlikely to benefit patients with KRAS-mutated colorectal cancer.
- KRAS mutation analysis should be considered in the clinical management of colorectal cancer patients.
Related Concept Videos
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...